No Data
No Data
Leerink Partners Maintains Exact Sciences(EXAS.US) With Buy Rating, Announces Target Price $100
Sector Update: Health Care Stocks Rise Pre-Bell Friday
Express News | Exact Sciences Shares up 1.2% Premarket After FDA Approves Co's Colorectal Cancer Screening Test
Express News | Exact Sciences Corp - Cologuard Plus Test Expected to Launch With Medicare Coverage in 2025
FDA Approves Exact Sciences' Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening
Express News | FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening
No Data
No Data